Erasca, Inc. (ERAS) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -302.68M USD | Operating Income (Loss) |
| Revenue | (m) | |
| Cost of products and services | (m) | |
| Research and development | (m) | |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-302.68M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-293.19M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-140.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-144.01M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-146.71M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-176.37M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-179.59M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-177.75M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-175.16M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-143.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-141.53M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $-245.73M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-248.03M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-247.97M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-247.45M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-140.42M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-149.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-141.78M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-124.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-109.25M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |